In this regard, TRAIL is specifically expressed in the brains of AD patients, which display a TRAIL-specific immunoreactivity mainly localized in AD-affected regions, such as the cerebral cortex, often in the proximity of Congo-red-positive amyloid plaques [78]. Here, TNFSF10 is linked to Alzheimer disease.